Treatment with a Catalytic Superoxide Dismutase (SOD) Mimetic Improves Liver Steatosis, Insulin Sensitivity, and Inflammation in Obesity-Induced Type 2 Diabetes by Coudriet, Gina et al.
antioxidants
Article
Treatment with a Catalytic Superoxide Dismutase
(SOD) Mimetic Improves Liver Steatosis, Insulin
Sensitivity, and Inflammation in Obesity-Induced
Type 2 Diabetes
Gina M. Coudriet 1,† ID , Meghan M. Delmastro-Greenwood 2,†, Dana M. Previte 1 ID ,
Meghan L. Marré 1, Erin C. O’Connor 1, Elizabeth A. Novak 1, Garret Vincent 1, Kevin P. Mollen 1,
Sojin Lee 2, H. Henry Dong 2 and Jon D. Piganelli 1,*
1 Department of Surgery, Children’s Hospital of Pittsburgh of UPMC, School of Medicine,
University of Pittsburgh, Pittsburgh, PA 15224, USA; gmr9@pitt.edu (G.M.C.); dmp51@pitt.edu (D.M.P.);
mem212@pitt.edu (M.L.M.); eco9@pitt.edu (E.C.O.); elizabeth.novak@chp.edu (E.A.N.);
gav10@pitt.edu (G.V.); kevin.mollen@chp.edu (K.P.M.)
2 Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, School of Medicine,
University of Pittsburgh, Pittsburgh, PA 15224, USA; meghan.delmastro@gmail.com (M.M.D.-G.);
sol24@pitt.edu (S.L.); dongh@pitt.edu (H.H.D.)
* Correspondence: jdp51@pitt.edu; Tel.: +1-412-692-7498
† These authors contributed equally to this work.
Received: 22 September 2017; Accepted: 31 October 2017; Published: 1 November 2017
Abstract: Oxidative stress and persistent inflammation are exaggerated through chronic over-nutrition
and a sedentary lifestyle, resulting in insulin resistance. In type 2 diabetes (T2D), impaired insulin
signaling leads to hyperglycemia and long-term complications, including metabolic liver dysfunction,
resulting in non-alcoholic fatty liver disease (NAFLD). The manganese metalloporphyrin superoxide
dismustase (SOD) mimetic, manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin (MnP),
is an oxidoreductase known to scavenge reactive oxygen species (ROS) and decrease pro-inflammatory
cytokine production, by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) activation. We hypothesized that targeting oxidative stress-induced inflammation with
MnP would assuage liver complications and enhance insulin sensitivity and glucose tolerance in
a high-fat diet (HFD)-induced mouse model of T2D. During 12 weeks of feeding, we saw significant
improvements in weight, hepatic steatosis, and biomarkers of liver dysfunction with redox modulation
by MnP treatment in HFD-fed mice. Additionally, MnP treatment improved insulin sensitivity and
glucose tolerance, while reducing serum insulin and leptin levels. We attribute these effects to
redox modulation and inhibition of hepatic NF-κB activation, resulting in diminished ROS and
pro-inflammatory cytokine production. This study highlights the importance of controlling oxidative
stress and secondary inflammation in obesity-mediated insulin resistance and T2D. Our data confirm
the role of NF-κB-mediated inflammation in the development of T2D, and demonstrate the efficacy of
MnP in preventing the progression to disease by specifically improving liver pathology and hepatic
insulin resistance in obesity.
Keywords: SOD mimetic; metalloporphyrin; inflammation; type 2 diabetes; NAFLD; obesity;
insulin resistance
1. Introduction
The prevalence of obesity continues to be a worldwide concern, and in the United States, roughly
one-third of the American adult population is considered to be obese [1]. Over-nutrition, a sedentary
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lifestyle, and genetic predisposition are strongly associated with the development of insulin resistance
and metabolic syndrome, both of which are major risk factors for developing type 2 diabetes (T2D) [2,3].
Increased central adiposity causes peripheral organs, like the liver, to become targets of ectopic fat
deposition, which can lead to non-alcoholic fatty liver disease (NAFLD), the most common liver
disorder in the Western world [4,5]. Consequently, over 90% of obese patients diagnosed with T2D
also have NAFLD [6], a condition that presents with hepatic insulin resistance [7,8].
The prevailing paradigm is that persistent adiposity, both central and peripheral, induces
oxidative stress and chronic inflammation [9–11], causing insulin resistance [12]. Inflammation and
more specifically, obesity-induced inflammation is controlled by the redox-dependent transcription
factor, NF-κB, which is elevated in many tissues in models of obesity [13,14]. Circulating levels of
NF-κB-dependent pro-inflammatory cytokines, chemokines, and acute phase proteins are also detected
in T2D [15]. Increased NF-κB activity and the ensuing inflammation contribute to the dysregulation
of insulin signaling at peripheral sites, like the liver [9,13,14,16], perpetuating NAFLD. As a result of
chronic inflammation, global insulin receptor signaling becomes desensitized, resulting in impaired
glucose metabolism [12,17,18].
Therefore, it is clear that persistent obesity-induced inflammation and oxidative stress can impact
the progression to NAFLD, insulin resistance, and resultant T2D. The manganese porphyrin superoxide
dismutase (SOD) mimetic, manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin (MnP) is
a first-in-class oxidoreductase that not only scavenges reactive oxygen species (ROS), like superoxide,
but also possesses anti-inflammatory properties [19] and has been proven clinically safe [20]. MnP has
been previously described as having positive effects in inflammatory-mediated disease models [21–28].
Work from our laboratory demonstrated that MnP inhibits inflammation by oxidation of the NF-κB
p50 subunit, thus impeding DNA-binding and in turn, transactivation [22]. Additionally, the ability
to scavenge superoxide by MnP results in the production of hydrogen peroxide, further contributing
to oxidation of NF-κB p50 [29]. Taken together, we hypothesized that MnP would be effective in
inhibiting obesity-induced NF-κB driven inflammation in the livers of obese mice, thus maintaining
glucose homeostasis and promoting insulin sensitivity, while diminishing NAFLD.
2. Materials and Methods
2.1. Cell Culture
The human hepatocellular carcinoma cell line, HepG2 (American Type Culture Collection (ATCC),
Manassas, VA, USA), was a generous gift from H. Henry Dong (University of Pittsburgh). The cells
were cultured in Eagle’s Minimum Essential Medium supplemented with 10% fetal bovine serum in
a 37 ◦C in a 5% CO2 humid air incubator.
2.2. Preparation of Palmitic Acid (PA) Solution
PA solution was prepared by conjugating the fatty acid (FA) with FA-free bovine serum albumin
(BSA; Sigma-Aldrich, St. Louis, MO, USA), as previously described [30]. Briefly, PA was dissolved
in preheated 0.1 N NaOH and diluted in prewarmed serum-free media, containing 12% (w/v) BSA,
to give a final FA concentration of 4.0 mM. Stock solution was sterile filtered.
2.3. Measurement of Superoxide by Dihydroethidium (DHE)
HepG2 cells were stimulated with 100 µM PA, with or without 68 µM MnP, for 24 h in serum
free media. Superoxide was measured using DHE (Molecular Probes, Waltham, MA, USA) by flow
cytometry as previously described [28,31]. DHE measures total superoxide production, specifically,
by the detection of 2-OH-ethidium by flow cytometry [31]. Briefly, after stimulation, cells were washed
with ice cold phosphate buffered saline (PBS) and loaded with 50 µM DHE for 20 min at 37 ◦C.
Mean fluorescence intensity (MFI) was read by a BD LSR II Flow Cytometer (BD Bioscience, San Jose,
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CA, USA) in the AmCyan channel using a 585/42 detector and 545LP filter [31]. DHE MFI is displayed
as normalized to untreated DHE loaded cells.
2.4. Mice and Treatment
C57BL/6J mice (Jackson Labs, Bar Harbor, ME, USA) were housed under specific pathogen-free
conditions in the Rangos Research Center at Children’s Hospital of Pittsburgh of UPMC. Animal
experiments were approved by the Institutional Animal Care and Use Committee of Children’s
Hospital of Pittsburgh (Assurance Number A3187-01) and were in compliance with the laws of the
United States of America. Male mice (6–8 weeks of age) were fed either standard chow diet or a high fat
diet (HFD) (Research Diets, Inc, New Brunswick, NJ, USA) consisting of 60% kcal fat for 12 weeks (n = 5
per group). MnP, a generous gift from James Crapo, MD (National Jewish Health), was prepared [21]
and used at 5 mg/kg subcutaneously every 3 days.
2.5. Body Weight and Liver Weight
Body weight was recorded weekly up until termination of the experiment. At the time of sacrifice,
whole livers were excised from individual animals, weighed, and photographed.
2.6. Comprehensive Diagnostic Panel
Blood samples from lean or HFD + MnP mice were collected for toxicity profiling using a VetScan
Comprehensive Diagnostic Profile with a VetScan Chemistry Analyzer (Abaxis, Union City, CA, USA).
Liver, kidney, and pancreatic dysfunction were tested.
2.7. Quantification of Hepatic Lipid Accumulation
At sacrifice, livers were excised, immediately snap frozen in liquid nitrogen, and stored at −80 ◦C.
Hepatic intracellular triglyceride (TG) content was determined by acetone extraction as previously
described and levels are defined as mg TG per gram of total liver protein [32].
2.8. Liver Histology
Liver tissue was harvested, fixed in 10% formalin, and embedded in paraffin, or incubated in 30%
sucrose and embedded in Tissue-Tek optimum cutting temperature (O.C.T.) Compound (Sakura Finetek
USA, Inc., Torrence, CA, USA). Paraffin sections, cut by the University of Pittsburgh Histology Core
Laboratory were stained with hematoxylin and eosin (H&E). Frozen sections were cut and stained
with Oil Red O by the core as well. Sections were visualized via an Axioplan 2 microscope (Zeiss,
Oberkochen, Germany). Staining was quantified using ImageJ Software (NIH, Bethesda, MD, USA).
2.9. 8-Hzydroxy-2’-deoxyguanosine (8-OHdG)
Paraffin sections were used for 8-OHdG immunofluorescence. Sections were deparaffinized,
rehydrated, and citric acid was used for antigen retrieval. Sections were blocked with 5% donkey
serum for 1 h at room temperature and then stained with the 8-OHdG primary antibody (Abcam,
Cambridge, MA, USA) overnight at 4 ◦C. The following day, sections were probed with a donkey
anti-mouse AlexaFluor555 tagged secondary antibody for 1 h at room temperature. Lastly, sections
were stained with 4′,6-diamidino-2-phenylinodle (DAPI) and coverslips were mounted. Sections were
imaged using an Olympus fluorescent microscope (Olympus, Center Valley, PA, USA). Three fields per
section were imaged and staining was quantified using ImageJ Software (NIH, Bethesda, MD, USA)
by a blinded researcher. Nuclei, positive for 8-OHdG staining, were divided by total viable nuclei to
give a percentage of positively stained nuclei.
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2.10. Serum Adipokine Measurement
After overnight fasting, blood samples were collected and serum adipokines were determined
by a Milliplex Mouse Serum Adipokine Panel (Millipore, Billerica, MA, USA), at 5, 10, and 12 weeks
of feeding.
2.11. Intraperitoneal Glucose Tolerance Test (IPGTT)
A 1.0 g/kg dose of a 10% glucose solution was administered intraperitoneally after overnight
fasting, after 10 weeks of HFD feeding. Blood samples were collected at 0, 30, 60, 90 and 120 min after
glucose injection. Blood glucose levels were measured using a glucometer (Ascensia Breeze 2, Bayer,
Leverkusen, Germany).
2.12. Insulin Tolerance Test (ITT)
A 0.75 U dose of insulin (HumulinR, Lilly USA, Indianapolis, IN, USA) was injected
intraperitoneally, under non-fasting conditions, after 12 weeks of HFD feeding. Blood glucose levels
were measured at 0, 15, 30, 60, 90, and 120 min, post-insulin injection, using a glucometer.
2.13. Homeostasic Model Assessment-Estimated Insulin Resistance (HOMA-IR)
Insulin sensitivity was estimated by the HOMA-IR index calculated by the following equation:
HOMA-IR = fasting glucose (mg/dL) × fasting insulin (U/mL) ÷ 405 [32].
2.14. Nuclear Protein Extractions and Electrophoretic Mobility Shift Assay (EMSA)
Nuclear proteins were extracted from frozen livers as previously described [33]. The DNA-binding
oligonucleotide and corresponding complementary strand for NF-κB, 5′-AGTTGAGGGGACTTT
CCCAGGC-3′, (Promega, Madison, WI, USA), was end-labeled with 32P. Nuclear liver extract
(36 µg), HeLa nuclear extract (positive control), and the cold competitor consisting of HeLa
nuclear extract incubated with 50-fold excess of the unlabeled NF-κB consensus DNA-binding
oligo were incubated with the 32P-labeled oligo. The samples were resolved in a 4% Acrylamide,
60:1 Acrylamide:Bisacrylamide gel. The gel was dried and exposed to film at −80 ◦C and
then developed.
2.15. Quantitative Real-Time PCR (qRT-PCR)
RNA isolation from liver tissue was performed (RNeasy Kit, Qiagen, Valencia, CA, USA),
and cDNA was synthesized (RT2 Frist Strand Kit Qiagen, Valencia, CA, USA). Gene-specific cDNA
was amplified and quantified in a real-time thermal iCycler system (BioRad, Hercules, CA, USA)
using SYBR Green all-in-one qPCR mix (GeneCopoeia, Rockville, MD, USA). The primer sequences
encoding transcripts for mouse tumor necrosis factor-α (tnfα), macrophage chemoattractant protein-1
(mcp1), inducible nitric oxide synthase (inos), and 50S ribosomal protein L15 (rplo) were: tnfα (FWD:
5′-TTCCGAATTCACTGGAGCCTCGAA-3′, REV: 5′-TGCACCTCAGGGAAGAATCTGGAA-3′); mcp1
(FWD: 5′-ATGCAGTTAACGCCCCACTC-3′, REV: 5′-CCCATTCCTTCTTGGGGTCA-3′); inos (FWD:
5′-CTGCTGGTGGTGACAAGCACATTT-3′, REV: 5′-ATGTCATGAGCAAAGGCGCAGAAC-3′);
and rplo (FWD: 5′-GGCGACCTGGAAGTCCAACT-3′, REV: 5′-CCATCAGCACCACAGCCTTC-3′).
2.16. Enzyme-Linked Immunosorbent Assay (ELISA)
The hepatic MCP-1 and TNF-α protein concentrations were measured by ELISA (Abcam,
Cambridge, MA, USA). Liver lysates were prepared using the Abcam supplied lysate buffer.
Absorbance was read at 450 nm, and hepatic cytokine content was determined as pg of cytokine
per mg of liver protein.
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2.17. Statistical Analysis
Data were analyzed using GraphPad Prism 6.0 (GraphPad, La Jolla, CA, USA). When two
variables were measured, data was analyzed by two-way analysis of variance (ANOVA) with a Tukey
or Bonferroni post-hoc analysis for multiple comparisons. When one variable was analyzed, a one-way
ANOVA with a Tukey post-test of multiple comparisons was used. When data from two groups was
compared, an unpaired t test was used. Data are shown as mean ± standard error of the mean (SEM)
or standard deviation (SD). A p value < 0.05 was considered statistically significant. All tests and
statistical parameters are indicated in the figure legends.
3. Results
3.1. MnP Diminishes Superoxide Production In Vitro
Oxidative stress is the detrimental basis for many inflammatory-mediated disease pathologies [34].
Treatment for these diseases, like T2D, include antioxidants, to scavenge free radicals that are
responsible for promoting inflammation [35,36]. Previous work from our group has demonstrated
MnP as a potent SOD mimetic, with catalytic and anti-inflammatory properties. Its ability to scavenge
superoxide in immune cells has been extensively shown [22,23,25,27,28]. MnP also protects pancreatic
β cells from oxidative damage [24,37,38]. In order to demonstrate that MnP would be an effective
hepatic antioxidant, we interrogated the human liver carcinoma cell line, HepG2, as a basis for
our study on obesity-induced NAFLD and T2D. Stimulation of HepG2 cells in vitro with palmitic
acid (PA) is a widely accepted experimental model of hepatocellular steatosis [39]. HepG2 cells
possess nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 3 (NOX3), responsible for
the generation of ROS, like superoxide [40]. Therefore, we used this model of PA-induced superoxide
production to demonstrate the ability of MnP to quell hepatic ROS. Our data show that HepG2 cells
stimulated with 100 µM of PA for 24 h [40] led to an increase in superoxide production, as measured
by DHE fluorescence (Figure 1). Treatment with 68 µM MnP was successful in scavenging superoxide,
by significantly reducing (p < 0.05) its production by DHE MFI. Therefore, we propose that MnP would
be an effective antioxidant in our in vivo model, capable of scavenging hepatic ROS and inhibiting
resultant inflammation.
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The HFD-fed mouse has been extensively studied and is a well-accepted model for obesity-
induced insulin resistance [41]. We employed this model to test our hypothesis that inhibition of 
inflammation by MnP improves glucose tolerance and insulin sensitivity in T2D. HFD-fed mice 
gained weight as expected; however, MnP treatment significantly reduced weight gain during HFD 
feeding (Figure 2). Lean mice gained significantly less weight than their HFD fed counterparts (p < 
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Figure 1. MnP diminishes superoxide production in vitro. HepG2 cells were treated with 100 µM of
PA, with or without 68 µM MnP, for 24 h. Cells were then loaded with DHE and read for fluorescence
by flow cytometry. Unt: untreated, MnP: 68 µM MnP alone, PA: 100 µM PA alone, PA + MnP: 100 µM
PA + 68 µM MnP. Data are displayed as mean fluorescence intensity (MFI) normalized to untreated
controls ± SEM. Significance was determined by t-test of a combined n = 5 experiments (* indicates
p < 0.05).
3.2. MnP Treatment Reduces Weight Gain and Imposes Minimal Toxicity
The HFD-fed mouse has been extensively studied and is a well-accepted model for obesity-
induced insulin resistance [41]. We employed this model to test our hypothesis that inhibition of
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inflammation by MnP improves glucose tolerance and insulin sensitivity in T2D. HFD-fed mice gained
weight as expected; however, MnP treatment significantly reduced weight gain during HFD feeding
(Figure 2). Lean mice gained significantly less weight than their HFD fed counterparts (p < 0.05) from
3 to 12 weeks. Significant differences in weight gain were detected between the HFD and HFD + MnP
treated mice from 4 to 12 weeks (p < 0.05). Moreover, significant weight gain between lean and
HFD + MnP mice was not observed until 7 weeks of feeding, lasting until 12 weeks (p < 0.05). These data
indicate that onset of high calorie-induced weight gain is diminished upon redox modulation.
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Amylase (U/L) 921.5 1042 1092 ns 
Blood Urea Nitrogen (mg/dL) 23.17 19.67 22.5 ns 
Calcium (mg/dL) 10.5 10.18 10.32 ns 
Creatinine (mg/dL) 0.1667 0.2 0.2 ns 
Globulin (g/dL) 2.167 2.317 1.85 ns 
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Total Bilirubin (mg/dL) 0.1833 0.2333 0.2333 ns 
Total Serum Protein (g/dL) 5.817 5.733 6.067 ns 
MnP treatment exhibits minimal toxicity, n = 5 mice per group. Significance was calculated based on 
mean and SD by one-way ANOVA, with a Tukey post-test of multiple comparisons. * indicates p ≤ 0.05. 
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Figure 2. MnP treatment reduces weight gain in high fat diet (HFD)-fed mice. Over 12 weeks of HFD
feeding, weights were recorded for Lean (empty squares, solid line), HFD (filled squares, solid line),
and HFD + MnP (filled squares, dashed line) mice, n = 5 mice per group. Data is displayed as
mean ± SEM. Significance was calculated by two-way ANOVA with a Tukey post-test of multiple
comparisons. Significant differences were observed between Lean and HFD starting at 3 weeks (#),
between HFD and HFD + MnP starting at 4 weeks (*), and between Lean and HFD + MnP starting at
7 weeks (†), all lasting the duration of the experiment.
Previous work has proven that MnP treatment is well-tolerated as it has passed extensive
safety-toxicology studies for parenteral therapy [20]. Specifically, in mice, the no observed adverse
effect level (NOAEL) was established to be 10 mg/kg/day after once-daily iv dosing for 18 days [20].
Based on these findings, we did not anticipate any toxicity in our study, since only 5 mg/kg dose of
MnP was administered, subcutaneously, every 3 days. In this study, to confirm that MnP treatment did
not cause toxicity that contributed to the loss in weight gain (Figure 2), a comprehensive diagnostic
profile was conducted, exa ining liver, kidn y, and pancreatic dysfunction (Table 1). No significant
toxicity was observed during this study and all values stayed within the normal clinical range [42].
Therefore, all observed improvements in weight, liver pathology, and diabetes in this study can be
attributed to the redox modulation of MnP.
Table 1. MnP treatment exhibits minimal toxicity.
A alyte Lean HFD HFD + MnP One-Way ANOVA
Albumin (g/dL) 2.617 3.433 4.233 * Lean vs. HFD + MnP
Alanine Aminotr nsfe as (U/L) 63 58.33 79 ns
Alkaline Phosphatase (U/ 55.17 54.5 54 ns
Amylase (U/L) 921.5 1042 1092 ns
Blood Urea Nitrogen (mg/dL) 23.17 19.67 22.5 ns
Calcium (mg/dL) 10.5 10.18 10.32 ns
Creatinine (mg/dL) 0.1667 0.2 0.2 ns
Globulin (g/dL) 2.167 2.317 1.85 ns
Glucose (mg/dL) 121.5 141.5 142.2 ns
Phosphorus (mg/dL) 8.75 8.083 7.833 ns
Potassium (mmol/L) 5.583 5.083 4.633 ns
Sodium (m ol/L) 151.5 150.8 152.5 ns
Total Bilirubin (mg/dL) 0.1833 0.2333 0.2333 ns
Total Serum Protein (g/dL) 5.817 5.733 6.067 ns
MnP treatment exhibits minimal toxicity, n = 5 mice per group. Significance was calculated based on mean and SD
by one-way ANOVA, with a Tukey post-test of multiple comparisons. * indicates p ≤ 0.05.
Antioxidants 2017, 6, 85 7 of 18
3.3. Redox Modulation Reduces Liver Steatosis and Hepatic Lipid Accumulation
In order to assess the degree of hepatic steatosis, mice were euthanized at 12 weeks and livers
were excised immediately thereafter, to be photographed and weighed, after 12 weeks of HFD feeding.
A clear difference in the size and degree of fat accumulation, based on color, was observed between the
groups (Figure 3A). HFD-feeding significantly increased liver weight compared to lean chow-feeding
(p ≤ 0.01), while MnP treatment significantly reduced liver weight (Figure 3B) (p ≤ 0.001), comparable
to that of lean mice. Liver sections were assessed for fat droplets by H&E staining and Oil Red O
staining (Figure 3C). Quantification of Oil Red O staining demonstrated that MnP treatment diminished
fat accumulation in HFD livers compared to untreated HFD livers (Figure 3D) (p ≤ 0.001). Further,
MnP treatment significantly reduced (p ≤ 0.05) the levels of intrahepatic triglycerides, as compared
to HFD alone (Figure 3E). Taken together, these data demonstrate that redox modulation by MnP
treatment reduces steatosis in HFD-induced obesity.
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feeding. Data are displayed as mean ± SD, n = 5 per group. Significance was calculated by one-way
ANOVA with a Tukey post-test of multiple comparisons. ** indicates p ≤ 0.01, *** indicates p ≤ 0.001;
(C) H&E (top row) and Oil Red O (bottom row) staining of livers after 12 weeks of HFD feeding, with or
without MnP treatment. Representative images are shown with a 20×magnification; (D) Quantification
of Oil Red O staining. Data are displayed as mean ± SD, n = 4 mice per group. Three images per
section were analyzed using Image J (NIH, Bethesda, MD, USA). Significance was calculated by t-tests.
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total liver protein, were measured by acetone extraction. Data are displayed as mean ± SD. n = 5 mice
per group. Significance was calculated by t-tests. * indicates p ≤ 0.05.
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3.4. Hepatic Insulin Resistance is Improved with MnP Treatment
After 10 weeks of HFD feeding, with and without MnP treatment, Intraperitoneal glucose
tolerance test (IPGTT) and Insulin tolerance test (ITT) were performed, in order to assess glucose
intolerance and insulin resistance. MnP treated animals exhibited significant improvements in glucose
tolerance, 60 and 90 min post-glucose challenge, as compared to HFD mice (p ≤ 0.05) (Figure 4A),
indicating enhanced glucose clearance. Improved glucose tolerance with MnP treatment also correlated
with improved insulin sensitivity at the same time points (p ≤ 0.01) (Figure 4B). Further, an estimation
of insulin sensitivity was calculated using HOMA-IR. The HOMA-IR score is derived from a calculation
accounting for the presence and extent of insulin resistance [43]. A higher HOMA-IR score translates
to increased insulin resistance. Here, the HOMA-IR score was significantly decreased (p ≤ 0.05) with
MnP treatment compared to HFD alone (Figure 4C). These results indicate enhanced insulin sensitivity
and improved glucose clearance due to MnP treatment, which can be attributed in part to the reduction
in hepatocellular lipids exhibited by these animals (Figure 3).
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Figure 4. Hepatic insulin resistance is improved with MnP treatment. (A) After 10 weeks of HFD
feeding, mice were fasted and subjected to an IPGTT. Data are displayed as mean ± SEM. Significance
was calculated by two-way ANOVA with a Bonferroni post-test of multiple comparisons. * indicates
p ≤ 0.05; (B) After 10 weeks of HFD feeding, mice were fasted and subjected to an ITT. Data displayed
as mean ± SEM. Significance was calculated by two-way ANOVA with a Bonferroni post-test of
multiple comparisons. ** indicates p ≤ 0.01; (C) HOMA-IR was calculated from these results. Data are
displayed as mean ± SEM. Significance was calculated by t-tests. * indicates p ≤ 0.05.
3.5. Insulin, Leptin, and Plas inogen ctivator Inhibitor Type-1 (PAI-1) Levels are Diminished Following
MnP Treatment
Since MnP reduced liver steatosis (Figure 3) and maintained insulin sensitivity (Figure 4),
we sought to determine whether MnP, in turn, would reduce the effects of these phenomena in our
disease model. Specifically, we examined hyperinsulinemia, hyperleptinemia, and the cardiovascular
risk factor, plasminogen activator inhibitor-1 (PAI-1).
Obesity causes hyperinsulinemia, as the pancreatic β cells produce excess insulin in an attempt to
compensate for insulin resistance in peripheral tissues [44]. To determine the effects of MnP on
hyperinsulinemia, we measured insulin in the sera of mice treated with MnP while on a HFD.
Redox modulation by MnP treatment diminished serum insulin levels compared to HFD-fed mice at
5 and 10 weeks of HFD feeding, with a significant reduction seen by 12 weeks (p ≤ 0.05) (Figure 5A)
indicating lessened hyperinsulinemia and improved utilization of insulin. Leptin is an adipokine
hormone involved in regulating food intake and energy metabolism [45] and leptin resistance has
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been associated with obesity and HFD-feeding, resulting in hyperleptinemia, a decreased satiated
feeling [46], and cardiovascular damage. To determine the effects of MnP on hyperleptinemia, leptin
was measured in the sera of mice in our model. MnP treatment significantly reduced fasting leptin
levels in HFD mice at 5 (p≤ 0.05), 10 (p≤ 0.001), and 12 weeks (p < 0.01) (Figure 5B). These observations
are consistent with the improved glucose metabolism seen in Figure 3A,B, and with the weight gain
reduction (Figure 1), suggesting that lower leptin resistance may preclude polyphagia during early
obesity onset.
Obesity induces a series of long-term complications, most notably, an increased cardiovascular
risk [47]. PAI-1 is an acute phase protein and primary inhibitor of both tissue-type and urokinase-type
plasminogen activators (tPA and uPA)—mediators of fibrinolysis [48,49]. PAI-1 levels are elevated by
its production from inflamed liver and adipose tissues [50–52]. Therefore, an elevated circulating level
of PAI-1 in obesity is considered a risk factor for thrombosis and atherosclerosis [51]. The ability to
ameliorate increases in PAI-1 is critical in reducing the cardiovascular risk seen in obesity. Therefore,
PAI-1 levels were measured in the sera of mice treated with MnP or control while on a HFD.
MnP treatment lowered plasma PAI-1 levels slightly at 10 weeks and significantly (p≤ 0.05) at 12 weeks
(Figure 5C). These results demonstrate MnP’s ability to improve obesity-induced cardiovascular risks.
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Figure 5. MnP treatment lowered serum adipokines. (A) serum insulin; (B) serum leptin and (C)
serum PAI-1 were measured at 5, 10, and 12 weeks of HFD feeding, n = 5 mice per group. Data are
displayed as mean± SEM. Significance was calculated by two-way ANOVA with a Bonferroni post-test
of multiple comparisons. * indicates p ≤ 0.05, ** indicates p ≤ 0.01 and *** indicates p ≤ 0.001.
3.6. Redox Modulation Minimizes Oxidative Stress-Induced DNA Damage and Pro-Inflammatory Cytokine
Production During HFD
Oxidative stress drives pro-inflammatory cytokine production, which exacerbates NAFLD and
T2D pathologies, mediated through oxidation damage to lipids, proteins, and DNA. We have
shown with an in vitro model of hepatic steatosis (Figure 1), that MnP quells superoxide levels
in response to palmitate stimulation. We next sought to determine whether MnP has similar effects
in vivo. To do so, we examined the effect of MnP on oxidative damage at the DNA level in livers
of mice treated with MnP. The interaction of the hydroxyl radical with the nucleobase, guanine,
forms 8-hydroxy-2′-deoxyguanosine (8-OHdG) [53]. Therefore, the formation of 8-OHdG is therefore
a powerful biomarker for the detection of oxidative stress. Indeed, immunofluorescent imaging showed
that a HFD significantly increased the levels of oxidative stress-induced DNA damage, by 8-OHdG
staining within the nuclei (Figure 6). Strikingly, MnP was able to significantly abolish the presence of
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8-OHdG staining in the hepatic nuclei of liver sections, with levels similar to the lean livers (Figure 6).
Taken together, MnP was demonstrated to be a potent hepatic antioxidant, both in vivo and in vitro.Antioxidants 2017, 6, 85  10 of 17 
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The redox-dependent regulation of inflammation is mediated through NF-κB-dependent
pro-inflammatory cytokine production. These cytokines are well-accepted mediators of hepatic
insulin resistance and are upregulated in obesity [13,14]. Levels of the pro-inflammatory cytokine,
TNFα, a potent inhibitor of insulin signaling and therefore a major contributor to insulin resistance,
are elevated in obese subjects [54,55]. MCP-1 is a chemokine that aids in this process by recruiting
macroph ges into liver and adipos issue, fueling the inflammatory cascade [56,57]. To etermine
the effects of MnP on NF-κB-mediated cytokine production, the expressions of MCP1 and TNFα were
measured in the livers of mice, treated with or without MnP, on HFD. We observed diminished levels of
hepatic MCP1 and TNFα gene expressions with MnP treatment (Figure 7A,B). To confirm, we measured
the protein levels of these pro-inflammatory mediators from liver tissue and saw significant decreases
(p ≤ 0.01) in HFD + MnP mice (Figure 7D,E). Previous studies have shown that NF-κB-dependent
inducible nitric oxide synthase (iNOS) plays an important role in insulin resistance [58] and that
liver-specific inhibition of iNOS reverses obesity-induced insulin resistance [59,60]. Here, we showed
diminished levels of hepatic iNOS expression upon redox modulation with MnP (Figure 7C).
These data further support the hypo hesis that redox modulation by MnP inhibits the NF-κB-dependent
production of pro-inflammatory cytokines.
3.7. MnP Treatment Inhibits Hepatic Nuclear NF-κB Binding
Previously, we demonstrated, in vitro, that MnP prevented the binding of NF-κB to its response
element site, more specifically through blocking of NF-κB p50 to its cognate DNA response element [22].
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In order to define the mechanism for the anti-inflammatory effects observed with MnP treatment
(Figure 7), we determined the degree of NF-κB binding in nuclear liver extracts from HFD fed mice
treated, with or without MnP, by EMSA. A significant reduction in hepatic nuclear NF-κB binding
was observed with MnP treatment of HFD fed mice (p ≤ 0.0001) (Figure 8). These data recapitulate,
for the first time in an in vivo model, the blocking of NF-κB DNA binding, correlating with the
anti-inflammatory and oxidoreductase mechanism of MnP, previously reported in vitro [22].
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Figure 7. Redox modulation and NF-κB inhibition have anti-inflammation effects in the liver.
After 12 weeks of HFD feeding, hepatic gene expression was measured by qRT-PCR for (A) MCP1;
(B) TNFα; and (C) inducible nitric oxide synthase (iNOS), with or without MnP treatment. Data are
displayed as mean ± SEM, n = 5 mice per group. After 12 weeks of HFD feeding, hepatic protein
expression was measured by ELISA, for (D) MCP-1 and (E) TNF-α, with or without MnP treatment.
Cytokine concentrations were normalized to protein concentration to yield pg of cytokine per mg of
protein. Data are displayed as mean ± SD, n = 5 mice per group. Significance was calculated by t-tests.
** indicates p ≤ 0.01.
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nuclear liver extracts from HFD and HFD + MnP mice were mixed with 32P-labeled NF-κB consensus
oligonucleotide for Electrophoretic Mobility Shift Assay (EMSA). Control samples included 32P-labeled
NF-κB probe alone, 32P-labeled NF-κB probe mixed with HeLa extract, and HeLa extract mixed with
50-fold excess unlabeled NF-κB consensus oligonucleotide. Samples were resolved on a gel. The image
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4. Discussion
During the course of chronic over-nutrition, glycemic control may fail, as a result of insulin
resistance. The mechanisms triggering insulin resistance are primarily mediated by oxidative stress
and inflammation [36]. Specifically, the liver becomes a sight of abnormal lipid deposition and immune
cell infiltrate. Treatment options to reduce the risk of insulin resistance and/or diabetic complications
are of major importance. We hypothesized that controlling oxidative stress-induced inflammation by
redox modulation and inhibiting hepatic NF-κB activation would assuage NAFLD as well as enhance
insulin sensitivity and glucose tolerance.
MnP ameliorates oxidative stress-induced inflammation in immune cells and pancreatic β
cells [23–25,27,28,37,38,57,61]; however, its role in the liver has not been previously investigated.
Here, we used a cell-based experimental system mimicking steatosis. Since HepG2 cells possess
NOX3, which is capable of producing superoxide, we anticipated MnP’s efficacy in this model.
MnP was able to decrease superoxide production in PA-stimulated HepG2 cells (Figure 1). Therefore,
these data set the precedence for using MnP in vivo, using the HFD-induced model of obesity,
insulin resistance, and steatosis. In fact, we were able to demonstrate a significant reduction
in oxidative DNA damage by MnP, by detection of 8-OHdG in the hepatocyte nuclei of liver
sections (Figure 6). Hepatocytes are a prime target in obesity-induced insulin resistance, as the
key mediators of glucose metabolism. Additionally, they are able to produce and secrete ROS,
resulting in downstream generation of NF-κB-dependent pro-inflammatory cytokines and acute-phase
proteins [10,12–14,39]—key mediators in insulin resistance. MnP clearly had an effect on hepatocytes,
but may also be playing an additional role with the resident and infiltrating hepatic macrophages
responsible for driving oxidative stress-induced inflammation. Future studies will elucidate the role of
MnP on quelling obesity-induced hepatic macrophage inflammation.
MnP treatment reduced weight gain in HFD-fed mice compared to untreated HFD-fed mice,
though HFD + MnP mice gained more weight than the lean mice did (Figure 2). This trend held
when comparing the livers of each group. Not only was there a gross difference between the groups
upon examining the excised livers (Figure 3A), there also was a significant difference in the weight of
livers from HFD + MnP mice, compared to the HFD mice (Figure 3B). This difference in weight can
be correlated with the reduced hepatic steatosis (Figure 3C,D) and hepatocellular triglyceride levels
following MnP treatment (Figure 3E), suggesting that MnP treatment prevents NAFLD in animals fed
a HFD. Notably, these results are not likely attributed to the toxicity of MnP treatment, as demonstrated
through assessing multiple diagnostic parameters (Table 1). MnP treatment displayed no organ toxicity,
correlating with its already documented safety profile [20].
Further, MnP improved glucose tolerance (Figure 4A) and diminished insulin resistance in HFD-fed
animals (Figure 4B,C). These findings point to a potential role for MnP in energy expenditure. We have
previously reported that MnP treatment enhances aconitase activity [26]—an enzyme involved in
the tricarboxylic acid cycle, which is a direct target of ROS. This would allow for stabilization of the
mitochondria leading to more efficient mitochondrial metabolism and improved insulin sensitivity [62].
Reduced serum insulin levels were also observed with MnP treatment, indicating improved insulin
signaling and diminished hyperinsulinemia (Figure 5A). These results indicate better glucose utilization,
likely caused by decreased inflammatory- and oxidative stress-mediated insulin insensitivity upon
MnP treatment. Furthermore, it has been previously described that MnP preserves pancreatic β cell
function [37,38]. Therefore, MnP treatment may also be promoting more functional β cells as well as
maintaining normal glucose-stimulated insulin secretion, which is generally defective in obesity.
In addition, a significant reduction in serum leptin was observed with MnP treatment (Figure 5B).
Leptin is an adipokine that links adiposity and the central nervous system, to reduce appetite and
enhance energy expenditure [63,64]. Proper leptin signaling can promote satiety and facilitate glucose
utilization, while improving insulin sensitivity [45]. Leptin resistance also occurs from increased
caloric intake, and under fasting conditions, elevated serum leptin levels are proportional to the mass
of adipose tissue and increase obesity-induced leptin resistance [65] resulting in hyperleptinemia.
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Indeed, MnP treatment reduced hyperleptinemia contributing to the decreased weight gain, adiposity,
and steatosis observed in the MnP treated animals.
Moreover, serum PAI-1 levels were reduced with MnP treatment (Figure 5C). MnP has been
shown to repress the expression of PAI-1 in prostate cancer by decreasing transcription factor p300
DNA binding to an hypoxia response element (HRE) motif within the PAI-1 gene promoter region [61].
Therefore, it is not surprising that MnP had effects on PAI-1 in our model. PAI-1 is an acute-phase
protein, produced by the endothelium, liver, and adipose tissue [51]. Obesity induces elevated PAI-1
levels concomitant with insulin resistance [50] and hepatic steatosis. Insulin resistance is a result
of elevated levels of TNF-α, which also enhances PAI-1 expression [55]; therefore, MnP-mediated
reduction in TNF-α and PAI-1 levels synergize to inhibit steatosis and would likely be effective in
reducing the risk for thrombosis and atherosclerosis [66].
The mechanism behind these striking effects can be attributed to a significant dampening of
inflammation (Figure 9). Obesity results in oxidative stress and chronic inflammation, which, in turn,
cause insulin resistance and dysregulation of lipid metabolism. Further, the culmination of oxidative
stress-induced ROS production leads to activation of the NF-κB pathway, which contributes to NAFLD
progression, from simple steatosis to a more inflammatory condition, non-alcoholic steatohepatitis,
(NASH) [67]. This suggests that the ability of MnP to combat oxidative stress and inflammation is
potentially relevant in the prevention of NAFLD and T2D. Here, we have shown for the first time
that blockade of hepatocyte-associated NF-κB activation by MnP (Figure 8) was able to ameliorate the
obesity-mediated T2D phenotype, by diminishing the levels of TNF-α, MCP-1, and iNOS (Figure 7A,B),
which are major inducers of NASH and insulin resistance [54,56].
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Increased caloric intake, coupled with decreased physical activity along with a genetic predisposition
can lead to reactive oxygen species (ROS) production and oxidative stress [2,3,9–11]. Uncontrolled
obesity-induced oxidative stress results in chronic inflammation and production and circulation of
NF-κB-dependent proinflammatory cytokines and chemokines, as well as additional production of
ROS [13–15], fueling a feedback loop. Inflammation can directly affect insulin signaling, resulting
in insulin resistance and hyperglycemia. This not only contributes to the progression of type 2
diabetes (T2D), but also exacerbates ROS production and oxidative stress. Consequently, these events
cause hepatic steatosis and subsequent non-alcoholic fatty liver disease (NAFLD), the hepatic
manifestation of met bolic yndrome. In addition, ther is a perpetuation of insulin resistanc , as well
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NF-κB activation by MnP was sufficient to diminish pro-inflammatory cytokine production, thereby
reducing weight gain, insulin resistance, and hepatic steatosis in HFD-fed mice.
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A different manganese porphyrin, manganese [19] tetrakis [6]-benzoic acid porphyrin
(MnTBAP), has also been investigated for its role in ameliorating the progression of obesity-induced
insulin resistance [68–70]. However, our study differs in that MnP not only acts as a free radical
scavenger [19,21,22,24,26,27,38], but its oxidoreductase activity endows it with powerful
anti-inflammatory activity [21,22,25,27]. This is primarily due to the positive charge of this class
of MnPs, whereas MnTBAP and other anionic or neutral charged compounds do not prevent NF-κB
p50 DNA binding [19]. Although controlling ROS the generation of ROS is important for ameliorating
insulin resistance, preventing inflammation is imperative, and both of these linked responses are
inhibited by MnP. This is underscored by the fact that MnP treatment reduced the hepatic gene and
protein expressions of MCP-1 and TNF-α. MCP-1 recruits macrophages into peripheral sites such as
the liver and adipose tissue, which drive the production of TNF-α, described as a potent instigator
of obesity-induced insulin resistance [54]. Further, since TNF-α, working synergistically with other
cytokines, can activate inducible iNOS expression in the liver [71], it is no surprise that MnP treatment
also diminished iNOS expression (Figure 7C).
5. Conclusions
In conclusion, this study revealed that inhibiting oxidative stress and NF-κB-mediated
inflammation has a marked impact on the progression of T2D, and in doing so, also maintains
metabolic homeostasis, thereby improving NAFLD and hepatic insulin resistance in obesity. Future
studies are necessary to determine how MnP affects food intake and energy expenditure in mice fed
a HFD as well as how it impacts hepatic macrophage recruitment and activation. As such, these
findings further elucidate the mechanism of NAFLD in T2D, and point to therapeutic opportunities.
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